Cervical cancer, though almost entirely preventable, continues to claim over 350,000 lives each year — most of them women in developing countries. India carries one of the heaviest burdens. But it doesn’t have to be this way. Science has handed us the tools — vaccines, DNA-based screening, and effective treatments. The real hurdle? Making sure these solutions reach everyone, regardless of gender, geography, or income.Understanding HPV: The Root CauseAt the heart of the cervical cancer crisis is the Human Papillomavirus (HPV), one of the most common sexually transmitted infections worldwide. Most HPV infections resolve on their own. But when certain high-risk genotypes persist, they can lead to various cancers — not just cervical, but also anal, penile, vulvar, vaginal, and oropharyngeal.According to the World Health Organization (WHO), virtually all cervical cancer cases are caused by HPV. Every eight minutes, a woman in India dies of this disease — a stark statistic for something that could be prevented with timely vaccination and screening.HPV Affects Men Too — And We’re Ignoring ItWhile cervical cancer has gained some attention, HPV-related cancers in men remain dangerously underdiagnosed. In 2019 alone, over 70,000 cancer cases in men were caused by HPV — a number many experts say is underestimated.This was underscored by a recent study presented at the 10th Asia Pacific AIDS and Co-Infections Conference in Japan. Conducted by Dr Prapti Gilada-Toshinwal at a Mumbai clinic, it screened 105 men who have sex with men. The findings were worrying — 62% had anal HPV infections, rising to nearly 69% among those living with HIV. Many were also battling other sexually transmitted infections, pointing to an urgent need for integrated sexual health services.Why DNA Screening is a GamechangerGlobally, experts agree that the best way to detect HPV is through DNA-based molecular tests. Traditional screening methods like Pap smears or VIA (Visual Inspection with Acetic Acid) are no longer considered scientifically adequate.Yet, India’s most recent National Family Health Survey revealed that only 1.2% of women aged 15–49 had ever been screened for cervical cancer. WHO recommends that 70% of eligible women should be screened — a target India is far from achieving.A Made-in-India BreakthroughIn a promising development, April 2025 saw the validation of Truenat HPV-HR Plus, India’s first indigenous point-of-care HPV DNA test. Developed by Molbio Diagnostics and approved by leading institutions like AIIMS Delhi and ICMR’s research bodies, Truenat can detect eight high-risk HPV genotypes responsible for most cervical cancers. It’s fast, affordable, and adaptable for rural clinics — exactly the kind of innovation needed to scale up screening access.The Vaccine That Works — Even in a Single DoseVaccination remains our most powerful tool. A WHO-IARC study, led in part by Indian researcher Dr Smita Joshi, revealed that even one dose of the HPV vaccine offers strong protection. This has led to WHO recommending a single-dose vaccine schedule for young girls.India’s own vaccine, Ceravac, developed by the Serum Institute, is approved for boys as well. Yet, a national rollout remains pending, even as a few states like Delhi and Punjab have begun pilot programs.Prevention Must Be InclusiveActivists like Vijay Nair of Udaan Trust stress the need to include men in both vaccination and screening programs. Anal cancers are often missed or misdiagnosed in men, especially those from marginalized communities. Without proper diagnostic facilities like anoscopy centres and broader awareness, many are left untreated — or worse, undiagnosed.The WHO has set ambitious targets to eliminate cervical cancer: vaccinate 90% of girls by age 15, screen 70% of women by 35 and 45, and treat 90% of cases. But meeting these goals demands more than science — it needs political will, public funding, and sustained awareness.